Stay updated on Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference4%

- Check28 days agoChange DetectedUpgrade applied: version updated from v3.0.2 to v3.1.0. No other substantive content changes detected.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision updated to v3.0.2 and Back to Top removed; no core content or critical information is affected.SummaryDifference0.2%

- Check50 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.2%

- Check57 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, as well as the introduction of various chemical compounds related to azacitidine and pembrolizumab. Notably, several previous entries related to genetic diseases and specific antineoplastic agents have been removed.SummaryDifference3%

- Check71 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%

Stay in the know with updates to Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page.